

DEMONSTRATION OF β 1H GLOBULIN IN PEMPHIGUS

Takeji Nishikawa,¹ Makoto Sugiura, Takashi Hashimoto,
Seiichi Kurihara and Noboru Tamura²

¹Department of Dermatology, Keio University School of Medicine, Tokyo 160,
and ²Department of Immunology, Institute of Basic Medical Sciences,
University of Tsukuba, Ibaraki 305, Japan

Abstract. β 1H globulin is a plasma protein which regulates the biologic activities of the major fragment of the 3rd complement component, C3b. The role of β 1H globulin in pemphigus was investigated using immunofluorescence in the present study. Lesional skin biopsies from patients with confirmed pemphigus demonstrated in-vivo deposition of β 1H in addition to C3 in all of four biopsies. Eight serum samples containing C3 fixing intercellular antibodies were then tested for the capacity to fix β 1H and other complement components. All eight pemphigus sera showed fixation of β 1H to the intercellular areas of normal human skin. C1q and C4 fixation by pemphigus sera was also demonstrated in 7 of 8 sera, respectively. The experiment using C2-deficient serum indicated that the fixation of β 1H by intercellular antibodies requires the activation of the classical complement pathway. These data suggested that β 1H, a co-factor of C3b inactivator, plays a role in the in-vivo regulation of complement activity and supplies additional evidence for the participation of complement system in the pathogenesis of pemphigus.

Key words: β 1H globulin; Pemphigus; Complement system; Complement immunofluorescence

The role of the complement system in pemphigus is not fully understood. In our previous studies, we have demonstrated complement-fixing intercellular (IC) antibodies in some sera of untreated pemphigus patients (1), and several investigations have shown much evidence that the complement system ought to play an important role in pemphigus acantholysis (2). Very recently, we obtained data showing that in-vitro complement activation by IC antibodies should occur via the classical complement pathway, followed by activation of the C3b amplification loop (3).

β 1H globulin is a recently characterized plasma protein which regulates the biologic activity of the major fragment of the 3rd complement component, C3b, which is the most biologically active part of the complement system (4). The major function of

this protein is to act as a co-factor for the C3b inactivator (C3bINA). Carlo et al. demonstrated the presence of β 1H in the dermo-epidermal junction of patients with systemic lupus erythematosus (SLE) (5) and in the basement membrane zone (BMZ) of patients with bullous pemphigoid (6, 7). Since β 1H is a co-factor for C3bINA, it binds to C3b and accelerates the cleavage of C3b to C3c and C3d fractions, which explains its presence in the skin.

This study was undertaken to determine whether β 1H is present in the lesional skin of pemphigus and to ascertain if IC antibodies will fix β 1H together with early complement components, C1q and C4 in-vitro.

MATERIALS AND METHODS

Four patients were studied who were clinically and histologically diagnosed as having pemphigus. Biopsy was performed by the standard technique, quick-frozen and cut in a cryostat at 4-6 μ m thickness. The sections were used unfixed. Each section of the lesional skin was stained for the presence of IgG, C3, C1q, C4 and β 1H, using immunofluorescence (IF) technique. For the staining, commercially available conjugates for human IgG, C1q, C4 and C3 were used. Anti- β 1H antiserum was prepared by immunizing rabbits with β 1H in Freund's complete adjuvant. The β 1H globulin was purified as previously described (4) and showed a single stained band upon analysis by sodium dodecyl sulphate polyacrylamide gel electrophoresis (8). For the staining of β 1H, the antiserum was used at 1:10 dilution and an indirect IF was used, employing fluorescein isothiocyanate (FITC) labelled goat anti-rabbit IgG as the second antibody. The antibody titre and the final dilution of the conjugates were as follows: for human IgG, 1:10 (Dakopatts Co., Denmark, γ -chain specific Lot 089A, DAKO antibody titre 200); for C1q, 1:10 (Behring Institute, W. Germany, Lot 1289D5H, specific antibody content, 2.0 mg/ml); for C4, 1:10 (Behring, Lot 129208A, specific antibody content, 2.5 mg/ml); for C3, 1:10 (Dakopatts Lot 124, DAKO antibody titre 100;

Table 1. Demonstration of β 1H globulin and complement components in the lesional skin of pemphigus

No.	Patients	Diagnosis	Immunofluorescence				
			β 1H	C3	C1q	C4	IgG
1	M. H.	P. vulgaris	+	+	+	+	+
2	R. A.	P. foliaceus	+	+	-	+	+
3	T. T.	P. foliaceus	+	+	-	-	+
4	T. S.	P. erythematousus	+	+	+	-	+

and for rabbit IgG, 1 : 16 (Dakopatts heavy and light chain specific, Lot 037). Eight serum samples from untreated pemphigus patients which contained C3-fixing IC antibodies were tested for the capacity to fix β 1H in vitro together with the early components of complement (C1q and C4) using complement IF. Each serum was tested for β 1H and complement fixation at 1 : 5 dilution. Fresh normal human serum (NSH) diluted 1 : 5 with Ca^{++} and Mg^{++} enriched phosphate-buffered saline (PBS, pH 7.2) was used as a source of complement and β 1H. Heat-inactivated NHS and C2-deficient human serum (9) (a gift from Dr Sheldon R. Pinnell, Duke University Medical Center, USA) were used as controls in complement IF. The procedure and specificity control tests for complement IF are described elsewhere (3).

RESULTS

The results of staining for IgG, C3, C1q, C4 and β 1H in the lesional skin of pemphigus patients are shown in Table 1. IgG and C3 were deposited in the IC areas of the lesional skin in all four biopsies. All of these skin biopsies showed positive β 1H binding in the same fashion as for IgG and C3. The intensity of the staining was similar as that of C3 (Fig. 1). C1q and C4 were also demonstrated in 2 of 4 biopsies, respectively. The staining pattern was the same in all complement components. By in vitro complement IF technique, all 8 pemphigus sera containing C3 fixing IC antibodies showed fixation of β 1H in the IC areas of the normal human skin at 1 : 5 serum dilution. Fixation of other early complement components of the classical pathway, C1q and C4, was also demonstrated in 7 of 8 serum samples, respectively. However, the use of C2-deficient serum as the complement source inhibited the fixation of C3 and β 1H, while the staining of C1q and C4 was not affected at all.

DISCUSSION

The role of β 1H in the complement system has only recently been appreciated. β 1H, also known as C3b

inactivator accelerator, is an abundant plasma protein and has a molecular weight of 150 000 daltons. It functions with and without C3bINA in regulating C3b activity (4). In vitro studies have shown an absolute requirement for β 1H in the conversions of fluid phase C3b to the inactive products C3c and C3d (10). Recently, a role for β 1H in regulating complement activity in vivo has been suggested by studies showing that β 1H is deposited with complement and immunoglobulin and the dermo-epidermal junction of both lesional and non-lesional skin of patients with SLE (5). Further evidence comes from similar findings in patients with bullous pemphigoid in which β 1H was demonstrated at the BMZ in every instance where C3 was found (6, 7). In addition, it was also shown that BMZ antibodies of bullous pemphigoid will fix β 1H in vitro and that β 1H binding by BMZ antibodies requires the activation of the classical complement pathway. In the present study, β 1H was demonstrated in the IC areas of the lesional skin in all four biopsies where C3 and other early complement components were shown. The staining pattern of β 1H was identical with that of C3 and other complement components. Although the role of the complement system in pemphigus has been very controversial, numerous previous investigations suggest local activation of the complement system (2). Our data provide further evidence favouring a role for complement activation in pemphigus, since β 1H is demonstrated in the exactly same site as that of complement components including C1q, C4 and C3. In addition, we have demonstrated that β 1H can be fixed in the IC areas of the normal skin by C3 fixing IC antibodies. This fact also suggests the association of β 1H in complement activation by IC antibodies in vitro. Substitution of C2-deficient serum as the complement source in the complement IC resulted in the inhibition of both C3 and β 1H staining, while the positive binding of C1q and C4 was not affected




Fig. 1. Deposition of β 1H globulin in the intercellular areas of the lesional skin from a pemphigus patient (T. T) ($\times 200$).

at all, suggesting that β 1H fixation by IC antibodies requires the activation of the classical complement pathway.

Thus, the presence of the complement regulating protein, β 1H, in the IC areas of the pemphigus skin and the fixation of β 1H by IC antibodies in vitro provides additional evidence of the participation of the complement system in pemphigus, although the definitive role of complement in the pathogenesis of pemphigus remains to be established.

ACKNOWLEDGEMENTS

We are most grateful to those who supplied us with the material, and to Mrs Yoshiko Fujii for her excellent technical assistance. This study was supported by research grants from the Ministry of Health and Welfare of Japan and from Keio University School of Medicine.

REFERENCES

1. Nishikawa, T., Kurihara, S., Harada, T., Sugawara, M. & Hatano, H.: Capability of complement fixation of pemphigus antibodies in vitro. *Arch Dermatol Res* 260: 1, 1977.
2. Jordon, R. D.: Complement activation in pemphigus. *J Invest Dermatol* 74: 357, 1980.
3. Hashimoto, T., Sugiura, M., Kurihara, S. & Nishikawa, T.: In vitro complement activation by intercellular antibodies. *J Invest Dermatol* 78: 316, 1982.
4. Whaley, K. & Ruddy, S.: Modulation of the alterna-

tive complement pathway by β 1H globulin. *J Exp Med* 144: 1147, 1976.

5. Carlo, J. R., Rothfield, N. F. & Ruddy, S.: Demonstration of β 1H globulin together with C3b in the dermal-epidermal junction of patients with systemic lupus erythematosus. *Arthr Rheum* 21: 13, 1979.
6. Carlo, J. R., Gammon, W. R., Sams, Jr, W. M. & Ruddy, S.: Demonstration of the complement regulating protein, β 1H in the biopsies from patients with bullous pemphigoid. *J Invest Dermatol* 73: 551, 1979.
7. Lee, C. W. & Jordon, R. E.: The complement system in bullous pemphigoid. VII. Fixation of the regulatory protein β 1H globulin by pemphigoid antibody. *J Invest Dermatol* 80: 465, 1980.
8. Fujita, T., Takata, Y. & Tamura, N.: Solubilization of immune precipitates by six isolated alternative pathway proteins. *J Exp Med* 154: 1743, 1981.
9. Levy, S. B., Pinnell, S. R., Meadows, L., Snydermann, R. & Ward, F. E.: Hereditary C2 deficiency associated with cutaneous lupus erythematosus. *Arch Dermatol* 115: 57, 1979.
10. Pangburn, M. K., Schreiber, R. D. & Muller-Eberhard, H. J.: Human complement C3b inactivator. Isolation, characterization and demonstration of an absolute requirement for the serum protein β 1H for the cleavage of C3b in C4b solution. *J Exp Med* 146: 257, 1977.

Received October 8, 1981

T. Nishikawa, M.D.
Department of Dermatology
Keio University School of Medicine
Tokyo 160
Japan